No Data
Climb Bio to Present at Upcoming Investor Conferences
Climb Bio Completes Transition To Immune-mediated Disease Focused Company; Expects Cash Runway Through 2027 To Enable Delivery Of Key Value Inflection Points
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19
News On Eliem Therapeutics Inc. (ELYM) Now Under CLYM
No Data
No Data